Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease - PubMed (original) (raw)

. 2021 Apr;19(4):806-815.e5.

doi: 10.1016/j.cgh.2020.06.045. Epub 2020 Jul 2.

Giada Sebastiani 2, Mauro Viganò 3, Javier Ampuero 4, Vincent Wai-Sun Wong 5, Jerome Boursier 6, Annalisa Berzigotti 7, Elisabetta Bugianesi 8, Anna Ludovica Fracanzani 9, Calogero Cammà 10, Marco Enea 11, Marraud des Grottes 12, Vito Di Marco 10, Ramy Younes 8, Aline Keyrouz 2, Sergio Mazzola [ 13](#full-view-affiliation-13 "Clinical Epidemiology and Cancer Registry Operative Unit, University Hospital Policlinico "Paolo Giaccone," Palermo, Italy."), Yuly Mendoza 7, Grazia Pennisi 10, Manuel Romero-Gomez 4, Antonio Craxì 10, Victor de Ledinghen 12

Affiliations

Free article

Salvatore Petta et al. Clin Gastroenterol Hepatol. 2021 Apr.

Free article

Abstract

Background & aims: Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events.

Methods: We performed a retrospective analysis of consecutive patients with NAFLD (n = 1039) with a histologic diagnosis of F3-F4 fibrosis and/or LSMs>10 kPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19-63 months).

Results: Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02-1.04; P < .001), HCC (HR, 1.03; 95% CI, 1.00-1.04; P = .003), and liver-related death (HR, 1.02; 95% CI, 1.02-1.03; P = .005). In 533 patients with available LSMs during the follow-up period, change in LSM was independently associated with hepatic decompensation (HR, 1.56; 95% CI, 1.05-2.51; P = .04), HCC (HR, 1.72; 95% CI, 1.01-3.02; P = .04), overall mortality (HR, 1.73; 95% CI, 1.11-2.69; P = .01), and liver-related mortality (HR, 1.96; 95% CI, 1.10-3.38; P = .02).

Conclusions: In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.

Keywords: NASH; Prognostic Factor; Steatohepatitis; cACLD.

Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources